Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine(Sanofi)

Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone Paris, February 3, 2023 Q4 2022 sales growth of 2.6% at CER and business EPS (1) growth of 17.4% at CER Specialty Care grew 18.1% driven by Dupixent ® (€2,402 million, +42.1%) and new product launches Vaccines sales (-16.3%) reflecting influenza and PPH sales phasing (Q3 influenza sales: up 32.4%) as well as ramp up of non-consolidated Vaxelis ® sales General Medicines core assets up 8.0% while GBU sales were lower (-3.7%) mainly due to Lantus ® and spin-off of EUROAPI CHC sales increased 6.6% driven by double-digit growth of Digestive Wellness, Cough & Cold and Allergy categories Full-year 2022 delivered 7.0% sales growth and 17.1% business EPS growth at CER Sales grew to €42,997 million driven by Dupixent ® (€8,293 million, +43.8%), adding €3 billion of incremental sales, Vaccines up 6.3% in line with the mid-term growth objective as well as CHC strategy execution (+8.6%) Mid-term BOI margin target of 30% and cost savings objective of €2.5 billion achieved Business EPS (1) of €8.26 up 25.9% on a reported basis and 17.1% at CER IFRS EPS of €5.37 (up 8.0%) Board held on February 2, proposes annual dividend of €3.56, an increase of 6.9% Progress on Corporate Social Responsibility strategy in Q4 Positive phase 2/3 results of acoziborole with the potential to further transform the treatment of sleeping sickness Accelerating our ambition towards net zero emissions by 5 years, now targeting 2045 Key R&D milestones and regulatory achievements in Q4 Dupixent ® approved in Europe for prurigo nodularis and CHMP positive opinion for eosinophilic esophagitis Beyfortus ® ( nirsevimab) approved in Europe for the prevention of RSV disease in all infants VidPrevtyn ® Beta approved in Europe as a booster for the prevention of COVID-19 in adults Enjaymo ® approved in Europe in adult patients with cold agglutinin disease (CAD) Full-year 2023 business EPS guidance Sanofi expects 2023 business EPS (1) to grow low single digit (2) at CER, barring unforeseen major adverse events. Applying average January 2023 exchange rates, the currency impact on 2023 business EPS is estimated between -3.5% to -4.5% Sanofi Chief Executive Officer, Paul Hudson, commented: “We closed 2022, marking the successful execution of the first chapter of our 6-year ‘Play to Win’ strategy. Specialty Care delivered the highest sales among our businesses. Dupixent ® and Vaccines continue to be our leading growth drivers. We are particularly proud of the progress we made in R&D transformation with multiple approvals of transformative medicines and new product launches across Specialty Care. At the same time, we keep delivering strong proof points of our improved financial performance underpinned by the achievement of the 30% BOI margin. Moving to the next chapter of our strategy, we are looking forward to the planned launches of Altuviiio ® and Beyfortus ® as well as key pivotal readouts, including the COPD indication for Dupixent ® . With the view on the expected entrants of generic competition for Aubagio ® in the coming months, we remain confident in our outstanding commercial capabilities, including the ambition to reach sales of 10 billion euros for Dupixent ® in 2023, enabling us to guide to low single-digit EPS growth for the year.” Q4 2022 Change Change at CER 2022 Change Change at CER IFRS net sales reported €10,725m +7.3% +2.6% €42,997m +13.9% +7.0% IFRS net income reported €1,460m +29.1% _ €6,720m +8.0% — IFRS EPS reported €1.16 +28.9% _ €5.37 +8.0% — Free cash flow (3) €2,546m +0.2% _ €8,483m +4.8% — Business operating income €2,724m +20.7% +15.0% €13,040m +21.7% +13.3% Business net income (1) €2,141m +23.8% +17.6% €10,341m +25.9% +17.0% Business EPS (1) €1.71 +23.9% +17.4% €8.26 +25.9% +17.1% Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (definition in Appendix 9). (1) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-GAAP financial measure (definition in Appendix 9). The consolidated income statement for Q4 2022 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4; (2) 2022 business EPS was €8.26; (3) Free cash flow is a non-GAAP financial measure (definition in Appendix 9). Attachment Press Release

While South African-based manufacturer Aspen looks at a possible change in direction for producing Covid-19 vaccines for the African continent, the company has secured a new contract with a major vaccine player. The Serum Institute of India and Aspen have entered into a 10-year agreement, in which Aspen will manufacture and distribute four of its vaccines for the African market, with some of those vaccines being available for The Serum Institute to also distribute on the continent. The deal will see Aspen produce its pneumococcal vaccine, rotavirus vaccine, polyvalent meningococcal vaccine and hexavalent vaccines, as The Serum Institute lends its expertise. On top of this work with The Serum Institute, Aspen also announced that it expects to receive grant funding from the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations (CEPI) to support vaccine manufacturing abilities in Africa. “The agreement concluded with the Serum Institute, and the anticipated grant funding from the Gates Foundation and CEPI, complement our previously stated commitment to expand sustainable and durable vaccine manufacturing on the continent to reduce Africa’s global vaccine dependency,” said Aspen CEO Stephen Saad in a statement. The vaccines will be produced at Aspen’s manufacturing facility in Gqeberha, South Africa, which was slated to make Covid-19 vaccines for the continent, but a lack of orders has impacted the facility. A Canadian CDMO has secured a $40 million Series A from a healthcare investment firm. AtomVie, a CDMO that manufactures radiopharmaceuticals, has received funding from Avego Management. AtomVie, a spinout from the Centre for Probe Development and Commercialization (CPDC), has been a radiopharma manufacturer for the past seven years but has only been a separate entity since last year. This boost of funding will go toward expanding its current GMP manufacturing capacity of radiopharma products to include commercial stage production. The company also plans to construct a new facility on the back of the raise to handle more isotopes. “The AtomVie team and its collective radiopharmaceutical expertise are second to none, and our partnership will advance the development of radiopharmaceuticals and improve patient outcomes,” said Thomas Vandervort, managing partner of Avego, in a statement . The cell and gene therapy CDMO Porton Advanced has had a busy end to August as the company secured two partnerships. The company first signed a collaboration with Suzhou Royaltech Med Co to work on jointly producing microbial vectors in gene therapy, as well as working to research and produce mRNA and bacterial drugs. Porton also netted a deal with the Kun Tuo Medical Research and Development Company, where both companies plan to cooperate in cell and therapy R&D, manufacturing and clinical research. The deal is aimed to provide research and CDMO services for drug companies in the cell and gene therapy space. However, no financial terms or timeline details have been disclosed for any of the deals currently. “We are very pleased to announce that we entered into a strategic partnership with Kun Tuo. Porton Advanced focuses on the field of gene and cell therapy and is committed to establishing a global, end-to-end CDMO service platform, while Kun Tuo delves into clinical research services and has very rich clinical resources as well as a highly professional clinical research & reporting team with strict quality standards,” said Porton CEO Wang Yangzhou in a statement.